Trevi Therapeutics Inc (TRVI)

$10.96 +0.81 (7.98%)
Market Cap 1.28B
Revenue (ttm) 0.00
Net Income (ttm) -47.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,621,900
Avg Vol 1,874,434
Day's Range N/A - N/A
Shares Out 128.23M
Stochastic %K 14%
Beta 0.91
Analysts Strong Sell
Price Target $21.08

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 304 2499
Address:
195 Church Street, 16th Floor, New Haven, United States
Chris2bucks4life
Chris2bucks4life Jan. 27 at 5:59 PM
$TRVI added 400 shares today
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 27 at 1:56 PM
$TRVI unbelievable smh
1 · Reply
abcdzepeda
abcdzepeda Jan. 24 at 3:44 AM
$TRVI Here is my two cents on what to expect in the short term with this awesome gem of a ticker. Jennifer should be announcing soon the results from her phase 3 study meeting with the FDA. As many of you know there is no approved therapy for chronic cough out in the market. I believe they give TRVI a fast track designation to bring this drug therapy for everyone who is suffering with chronic cough. Once the street hears this news we will see a nice move up, and analyst will start raising their price target. I believe this news is right around the corner, so we just need to be patient and do not expect any serious movement until that happens. JMO!
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 23 at 5:58 PM
$TRVI will double up in the 7's looks like we are headed there
0 · Reply
jlcrane
jlcrane Jan. 23 at 5:50 PM
$TRVI Very low volume means all the little tourists are getting out.
0 · Reply
Butch44
Butch44 Jan. 23 at 4:34 PM
$TRVI biotech stocks can drop for no other reason than investors don't have the patience to wait and MM's know this so the stock can be easily manipulated. Unless there is a buyout, it could go on for quite a while until they get real concrete news and analyst sales projections are much closer to fruition. 
0 · Reply
vcman
vcman Jan. 23 at 3:46 PM
$TRVI They can drop us 5-10% on no volume and they did. More importantly, the data is good. For patients coughing over 30 times per hour and can see that reduced to around 12 is significant. Placebo had no meaningful effect on cough frequency. I haven't yet seen any analyst reports tearing apart the results, but to me those that are selling don't fully understand the trial study or the resulting data.
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 23 at 3:40 PM
$TRVI just love how they can drop us 8 to ten percent on a measly hundred thousand shares!
0 · Reply
drewboca
drewboca Jan. 23 at 4:07 AM
$TRVI so it only works on 6 out of ten How did it work on placebo?
1 · Reply
Jimbob3016
Jimbob3016 Jan. 22 at 7:56 PM
$TRVI the news is not out yet to everyone still fresh imo
0 · Reply
Latest News on TRVI
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Jan 22, 2026, 12:30 PM EST - 5 days ago

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:30 AM EST - 19 days ago

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Dec 4, 2025, 7:30 AM EST - 7 weeks ago

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Dec 3, 2025, 2:16 PM EST - 7 weeks ago

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 9:21 PM EST - 2 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 4:05 PM EST - 2 months ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Nov 6, 2025, 4:05 PM EST - 2 months ago

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:30 AM EST - 3 months ago

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Oct 8, 2025, 7:30 AM EDT - 3 months ago

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 18, 2025, 7:30 AM EDT - 4 months ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 7:15 PM EDT - 5 months ago

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 28, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:47 PM EDT - 6 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 31, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 29, 2025, 7:30 AM EDT - 6 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 5, 2025, 4:30 PM EDT - 8 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 3, 2025, 10:15 PM EDT - 8 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 8 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 1:42 PM EDT - 8 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 8 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Participate in Upcoming June Conferences

May 29, 2025, 7:30 AM EDT - 8 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 20, 2025, 7:00 AM EDT - 9 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:16 AM EDT - 9 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 4:05 PM EDT - 9 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

May 1, 2025, 4:05 PM EDT - 9 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Apr 3, 2025, 7:30 AM EDT - 10 months ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 6:47 PM EDT - 11 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 11, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Mar 10, 2025, 11:30 AM EDT - 11 months ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Mar 10, 2025, 6:00 AM EDT - 11 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Mar 9, 2025, 4:00 PM EDT - 11 months ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 7:30 AM EST - 11 months ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Feb 25, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 30, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 16, 2024, 7:36 AM EST - 1 year ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 9:47 AM EST - 1 year ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 12, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Dec 3, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:54 PM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 21, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Chris2bucks4life
Chris2bucks4life Jan. 27 at 5:59 PM
$TRVI added 400 shares today
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 27 at 1:56 PM
$TRVI unbelievable smh
1 · Reply
abcdzepeda
abcdzepeda Jan. 24 at 3:44 AM
$TRVI Here is my two cents on what to expect in the short term with this awesome gem of a ticker. Jennifer should be announcing soon the results from her phase 3 study meeting with the FDA. As many of you know there is no approved therapy for chronic cough out in the market. I believe they give TRVI a fast track designation to bring this drug therapy for everyone who is suffering with chronic cough. Once the street hears this news we will see a nice move up, and analyst will start raising their price target. I believe this news is right around the corner, so we just need to be patient and do not expect any serious movement until that happens. JMO!
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 23 at 5:58 PM
$TRVI will double up in the 7's looks like we are headed there
0 · Reply
jlcrane
jlcrane Jan. 23 at 5:50 PM
$TRVI Very low volume means all the little tourists are getting out.
0 · Reply
Butch44
Butch44 Jan. 23 at 4:34 PM
$TRVI biotech stocks can drop for no other reason than investors don't have the patience to wait and MM's know this so the stock can be easily manipulated. Unless there is a buyout, it could go on for quite a while until they get real concrete news and analyst sales projections are much closer to fruition. 
0 · Reply
vcman
vcman Jan. 23 at 3:46 PM
$TRVI They can drop us 5-10% on no volume and they did. More importantly, the data is good. For patients coughing over 30 times per hour and can see that reduced to around 12 is significant. Placebo had no meaningful effect on cough frequency. I haven't yet seen any analyst reports tearing apart the results, but to me those that are selling don't fully understand the trial study or the resulting data.
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 23 at 3:40 PM
$TRVI just love how they can drop us 8 to ten percent on a measly hundred thousand shares!
0 · Reply
drewboca
drewboca Jan. 23 at 4:07 AM
$TRVI so it only works on 6 out of ten How did it work on placebo?
1 · Reply
Jimbob3016
Jimbob3016 Jan. 22 at 7:56 PM
$TRVI the news is not out yet to everyone still fresh imo
0 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 22 at 6:11 PM
$TRVI sell the rumor and sell the news i guess
0 · Reply
jlcrane
jlcrane Jan. 22 at 5:36 PM
$TRVI The stock should be up $4 minimum on this news.
1 · Reply
jlcrane
jlcrane Jan. 22 at 5:35 PM
$TRVI This latest news release is significant. The stock pops, and then retreats some, this after a 40% decline from the highs. What gets this stock going again? What is the street looking for?
2 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 21 at 7:09 PM
$TRVI xbi up trvi down xbi down trvi down more unbelievable smh
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 20 at 5:13 PM
$TRVI grrrrrrr
1 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 20 at 1:19 PM
$TRVI looks like we will get smoked again this week
0 · Reply
vcman
vcman Jan. 17 at 5:40 PM
$TRVI I still like the science and the clinical markets they are targeting are excellent. As of recent, my view of management...
0 · Reply
Brutusmabel
Brutusmabel Jan. 16 at 8:25 PM
$SIDU here’s my other pick from proceeds today , $TRVI, good entry point and it’s been a steady beast over the past 12 months up from $3-$10. That and $IREN are my two investments off today’s proceeds 👍 like imo said before glta and feel free to follow
0 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 16 at 4:54 PM
$TRVI market green trivi down market red trvi down
0 · Reply
vcman
vcman Jan. 16 at 4:41 PM
$TRVI Pathetic trading...back to October levels, ugh. They stated last week that end-of-phase 2 meeting with FDA is scheduled for some time during Q1 but won't say when. No other significant updates which is annoying particularly with a new CFO. Both he and Jennifer need to be reminded that TRVI is a publicly traded company.
1 · Reply
Soheil444
Soheil444 Jan. 15 at 10:02 PM
$TRVI Glad i got out
3 · Reply
Chris2bucks4life
Chris2bucks4life Jan. 15 at 8:26 PM
$TRVI stellar day
0 · Reply